PrintHEALTHCARE REFORM:
FTC: Pay-for-Delay Costing Taxpayers BillionsAgency report finds 60 percent increase in deals where pharma companies pay generic drugmakers to hold off entering the market.
So-called pay-for-delay deals between pharmaceutical companies and generic rivals grew by more than 60 percent in fiscal 2010, according to a new report from the Federal Trade Commission, which continues to push to outlaw such agreements. The agency says the deals come at a hefty price tag to taxpayers who pay billions of dollars more for drugs because they delay the entry of lower-priced generics into the market.
Read More
Read More
Regenerative Medicine
Stem Cell Injunction Lifted, but Fight RemainsPodcast: May 9, 2011 Read More.Biofuel
Making a Case for BiofuelsReport says they can contribute to significant greenhouse gas reductions. Read More.Comparative Effectiveness
A Near-TieStudy shows two Genentech drugs almost equally effective for eye disease. Read More.Legislation
Feds Turning up the Heat on Off-Label Marketing ViolatorsHHS Office of Inspector General considers excluding Forest Lab’s CEO from doing business with the government. Read More.Patents
BIO Sours on Patent Reform LegislationIndustry wants to kill amendment before floor vote. Read More.Healthcare Reform
Avoiding a Medical MeltdownPodcast: April 18, 2011 Read More.Healthcare Reform
Obama’s Deficit Reduction Plan Includes Cuts in Health CareClaims of $500 million in savings by 2023, more than $1 trillion by 2033. Read More.Commentary
Separate and UnequalGeneric substitution, while a good way to save payers money in the short-term, often has deleterious impact on patient care. Read More.Conflicts of Interest
Pharma Companies Disclose Millions Paid to U.S. DoctorsVoluntary reporting accelerates ahead of new requirements Read More.Biofuel
Obama Outlines U.S. Energy Security PlanPresident pledges support for development of advanced biofuels. Read More.Commentary
Biosimilars Present Opportunities and Challenges to RussiaIf country hopes to export these medicines, a 21st century, state of the art, internationally recognized and harmonized regulatory system will be a fundamental requirement. Read More.Biofuel
U.S. and Brazil Expand Agreement to Include Aviation BiofuelsBrazillian industry group calls development an encouraging step toward the end of tariff that keeps corn-derived ethanol competitive with sugar-cane derived fuel. Read More.Healthcare Reform
Brand Name Drug Prices Rise Faster than Medical InflationGeneric drugs fall at an annual rate of 2.6 percent since 2006. Read More.Regulatory
A Step Closer to RegulationFDA advisory panel calls for physician supervision of direct-to-consumer genetic tests. Read More.Healthcare Reform
Getting Rewarded to Stay WellHHS announces $100 million in Affordable Care Act grants to prevent disease. Read More.
- Court backs federal embryonic stem cells funds
Reuters - A Fight Over How Drugs Are Pitched
The New York Times - White House announces plans to reduce prescription drug
Reuters - U.S. Cancer Doctors Back Genetic Tests to Assess Lung Cancer Patients
Bloomberg - Endo cuts patent risk with $2.6 billion American Medical
Reuters - Republican Medicare Plan Could Shape 2012 Races
The New York Times - Sanofi Chief details innovation strategy
Boston Business Journal - Cephalon Board Rejects Valeant’s Unsolicited $5.7 Billion Bid As Too Low
Reuters - Mouse Stem-Cell Discovery May Lead to Blindness Therapies, Researchers Say
Bloomberg - Drugs’ Cost and Safety Fuel a Fight
The New York Times